ESC 365 - Optimising P2Y12 inhibition in real world clinical practice: clinical outcomes of prasugrel and ticagrelor.

ESC Premium Access

Optimising P2Y12 inhibition in real world clinical practice: clinical outcomes of prasugrel and ticagrelor.

Session: Potent P2Y12 receptor inhibition – What can we learn from clinical practice?

Topic: Thrombosis and platelets

Speaker: Professor J. Jukema (Leiden, NL)

Sponsored by Daiichi Sankyo Europe GmbH

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Professor J Wouter Jukema

Leiden University Medical Center, Leiden (Netherlands (The))

20 presentations

0 follower

3 more presentations in this session

Welcome & introduction: Potent P2Y12 receptor inhibition – What can we learn from clinical practice?

Speaker: Professor K. Huber (Vienna, AT)

How to apply guidelines to clinical practice.

Speaker: Professor A. Schaefer (Hannover, DE)

Discussion – Summary and closing remarks: potent P2Y12 receptor inhibition – What can we learn from clinical practice?

Speaker: Professor K. Huber (Vienna, AT)

Access the full session

Potent P2Y12 receptor inhibition – What can we learn from clinical practice?

Speakers: Professor J. Jukema, Professor K. Huber, Professor A. Schaefer, Professor K. Huber

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources